Fortunately, recent developments in therapeutics suggest new approaches to improve outcomes in DKD [3], including the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, and third generation mineralocorticoid receptor antagonists. Here, NR3C2 is linked to diabetic kidney disease.